This 190-page “AI for Drug Discovery, Biomarker Development and Advanced R&D Landscape Overview Q2 2021” report marks the ninth installment in a series of reports on the topic of the Artificial Intelligence (AI) application in pharmaceutical research industry that DKA Pharma Division have been producing since 2017.

​

The main aim of this series of reports is to provide a comprehensive overview of the industry landscape in what pertains adoption of AI in drug discovery, clinical research and other aspects of pharmaceutical R&D. This overview highlights trends and insights in a form of informative mind maps and infographics as well as benchmarks the performance of key players that form the space and relations within the industry. This is an overview analysis to help the reader understand what is happening in the industry nowadays and possibly give an idea of what is coming next.